Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer

The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial. Sixty-three patients with MBC, previously treated with chemotherapy inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorusso, V, Crucitta, E, Silvestris, N, Catino, A, Caporusso, L, Mazzei, A, Guida, M, Latorre, A, Sambiasi, D, D'Amico, C, Schittulli, F, Calabrese, P, De Lena, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377160/
https://www.ncbi.nlm.nih.gov/pubmed/12592360
http://dx.doi.org/10.1038/sj.bjc.6600780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377160/
https://www.ncbi.nlm.nih.gov/pubmed/12592360
http://dx.doi.org/10.1038/sj.bjc.6600780

Ejemplares similares